Authors
Vetter ML, Cardillo S, Rickels MR, et al.
Institution
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. marion.vetter@uphs.upenn.edu
Source
Ann Intern Med 2009 Jan 20; 150(2)
:94-103.Abstract
Bariatric surgery leads to substantial and durable weight reduction. Nearly 30% of patients who undergo bariatric surgery have type 2 diabetes, and for many of them, diabetes resolves after surgery (84% to 98% for bypass procedures and 48% to 68% for restrictive procedures). Glycemic control improves in part because of caloric restriction but also because gut peptide secretion changes. Gut peptides, which mediate the enteroinsular axis, include the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, as well as ghrelin and peptide YY. Bariatric surgery (particularly bypass procedures) alters secretion of these gut hormones, which results in enhanced insulin secretion and sensitivity. This review discusses the various bariatric procedures and how they alter the enteroinsular axis. Familiarity with these effects can help physicians decide among the different surgical procedures and avoid postoperative hypoglycemia.
Mesh
Bariatric SurgeryBlood GlucoseCaloric RestrictionDiabetes Mellitus, Type 2Gastrointestinal HormonesHumansInsulinObesityWeight LossLanguage
eng
Pub Type(s)
Journal Article
PubMed ID
19153412